Biocept, Inc. (BIOC)
Total Valuation
Biocept has a market cap or net worth of $1.28 million. The enterprise value is $6.09 million.
| Market Cap | 1.28M |
| Enterprise Value | 6.09M |
Important Dates
The last earnings date was Wednesday, May 10, 2023, after market close.
| Earnings Date | May 10, 2023 |
| Ex-Dividend Date | n/a |
Share Statistics
Biocept has 592,906 shares outstanding. The number of shares has increased by 4.57% in one year.
| Shares Outstanding | 592,906 |
| Shares Change (YoY) | +4.57% |
| Shares Change (QoQ) | +3.27% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 7.99% |
| Float | 592,722 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.11 |
| Forward PS | 0.16 |
| PB Ratio | 0.53 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.54 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.07, with a Debt / Equity ratio of 4.77.
| Current Ratio | 2.07 |
| Quick Ratio | 1.80 |
| Debt / Equity | 4.77 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
Financial Efficiency
Return on equity (ROE) is -208.30% and return on invested capital (ROIC) is -111.60%.
| Return on Equity (ROE) | -208.30% |
| Return on Assets (ROA) | -83.90% |
| Return on Capital (ROIC) | -111.60% |
| Revenue Per Employee | $227,560 |
| Profits Per Employee | -$644,580 |
| Employee Count | 50 |
| Asset Turnover | 0.30 |
| Inventory Turnover | 10.77 |
Taxes
| Income Tax | -125,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -94.86% in the last 52 weeks. The beta is 0.92, so Biocept's price volatility has been similar to the market average.
| Beta (1Y) | 0.92 |
| 52-Week Price Change | -94.86% |
| 50-Day Moving Average | 8.27 |
| 200-Day Moving Average | 18.20 |
| Average Volume (30 Days) | 132,156 |
Short Selling Information
The latest short interest is 235,195, so 39.67% of the outstanding shares have been sold short.
| Short Interest | 235,195 |
| Short Previous Month | 307,817 |
| Short % of Shares Out | 39.67% |
| Short % of Float | 39.68% |
| Short Ratio (days to cover) | 3.06 |
Income Statement
In the last 12 months, Biocept had revenue of $11.38 million and -$32.23 million in losses. Loss per share was -$56.70.
| Revenue | 11.38M |
| Gross Profit | -9.76M |
| Operating Income | -32.14M |
| Pretax Income | -32.35M |
| Net Income | -32.23M |
| EBITDA | -30.06M |
| EBIT | -32.05M |
| Loss Per Share | -$56.70 |
Balance Sheet
The company has $6.77 million in cash and $11.58 million in debt, giving a net cash position of -$4.81 million or -$8.11 per share.
| Cash & Cash Equivalents | 6.77M |
| Total Debt | 11.58M |
| Net Cash | -4.81M |
| Net Cash Per Share | -$8.11 |
| Equity / Book Value | 2.43M |
| Book Value Per Share | 4.10 |
| Working Capital | 4.70M |
Cash Flow
In the last 12 months, operating cash flow was -$18.55 million and capital expenditures -$800,000, giving a free cash flow of -$19.35 million.
| Operating Cash Flow | -18.55M |
| Capital Expenditures | -800,000 |
| Free Cash Flow | -19.35M |
| FCF Per Share | -$32.95 |
Margins
Gross margin is -85.75%, with operating and profit margins of -282.48% and -283.26%.
| Gross Margin | -85.75% |
| Operating Margin | -282.48% |
| Pretax Margin | -284.36% |
| Profit Margin | -283.26% |
| EBITDA Margin | -264.23% |
| EBIT Margin | -281.72% |
| FCF Margin | -170.07% |
Dividends & Yields
Biocept does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Earnings Yield | -2,516.56% |
| FCF Yield | -1,511.00% |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.57% |
| Shareholder Yield | -4.57% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on May 17, 2023. It was a reverse split with a ratio of 1:30.
| Last Split Date | May 17, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:30 |